Drugs / Diacerein
Trials 33
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03472287 | May 2018 → Jan 2019 | epidermolysis bullosa dystrophica, epidermolysis bullosa simplex, junctional epidermolysis bullosa | Castle Creek Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03472547 | Jan → Mar 2018 | — | Castle Creek Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03472534 | Jan 2018 | — | Castle Creek Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03473197 | Jan → Mar 2018 | — | Castle Creek Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03473184 | Dec 2017 | — | Castle Creek Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 213 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT06972888 | Apr 2024 → Mar 2025 | psoriasis | Accro Bioscience (Suzhou) Limited | Completed | No outcome recorded |
| Phase 2 | NCT04917679 | Sep 2020 → Dec 2021 | primary thrombocytopenia | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Phase 2 | NCT03754634 | May 2019 → Jun 2020 | thrombocytopenia | Shandong University | Completed | No outcome recorded |
| Phase 2 | NCT03468322 | Oct 2018 → Apr 2019 | inherited epidermolysis bullosa | TWi Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03389308 | Dec 2017 → Apr 2020 | epidermolysis bullosa simplex | Castle Creek Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03286582 | Sep 2017 → Dec 2018 | bullous pemphigoid | TWi Biotechnology, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03154333 | Jun 2017 → Oct 2018 | epidermolysis bullosa simplex | Castle Creek Pharmaceuticals, LLC | Terminated | Missed primary |
| Phase 2 | NCT02994147 | Mar 2017 → Apr 2019 | hemophilic arthropathy | TWi Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02287818 | Dec 2014 → Oct 2016 | gout | TWi Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01712204 | Jan → Sep 2013 | gout | TWi Biotechnology, Inc. | Completed | Missed primary |
| Phase 2 | NCT01276106 | Jan 2011 → Feb 2012 | type 2 diabetes mellitus | TWi Biotechnology, Inc. | Completed | Met primary |
| Phase 2 | NCT01264211 | Oct 2010 → Jun 2012 | rheumatoid arthritis | TRB Chemedica | Completed | Missed primary |
| Phase 2 | NCT01298882 | — | obesity disorder, type 2 diabetes mellitus | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06912035 | Jun → Nov 2024 | hyperglycemia, type 2 diabetes mellitus | Universitas Sriwijaya | Completed | No outcome recorded |
| Phase 2/3 | NCT06073132 | Apr 2024 → Jun 2026 overdue | epidermolysis bullosa simplex | TWi Biotechnology, Inc. | Active not recruiting | No outcome recorded |
| Phase 34 trials · 3 met primary | ||||||
| Phase 3 | NCT04318041 | Nov 2020 → Dec 2026 expected | osteoarthritis, knee | TRB Chemedica | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02688400 | May 2016 → Jun 2018 | osteoarthritis, knee | TRB Chemedica International SA | Completed | Met primary |
| Phase 3 | NCT02242149 | Oct 2014 → Jan 2017 | NAFLD1, type 2 diabetes mellitus | Federal University of Rio de Janeiro | Completed | Met primary |
| Phase 3 | NCT00451360 | Mar 1993 → Apr 1997 | osteoarthritis, hip | Laboratoires NEGMA | Completed | Met primary |
| Phase 48 trials · 1 missed | ||||||
| Phase 4 | NCT07352306 | Feb 2026 → Feb 2027 expected | psoriasis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03404479 | Jan 2018 → Jan 2019 | osteoarthritis, knee | Whan-Seok Choi | Unknown | No outcome recorded |
| Phase 4 | NCT01906801 | Jul 2013 → Oct 2014 | osteoarthritis, knee | Ramathibodi Hospital | Completed | Missed primary |
| Phase 4 | NCT02060552 | Jan 2013 → Mar 2014 | gout | Tongji Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00685542 | Jun 2008 → Oct 2009 | osteoarthritis, hand | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00440661 | Mar 2007 → Oct 2008 | osteoarthritis | Laboratoires NEGMA | Completed | No outcome recorded |
| Phase 4 | NCT01120015 | Jan 2007 → Jun 2008 | osteoarthritis, knee | Government Medical College, Amritsar | Completed | No outcome recorded |
| Phase 4 | NCT00445276 | Nov 2005 → Sep 2006 | osteoarthritis, knee | Laboratoires NEGMA | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07199933 | Oct 2025 → Oct 2026 expected | metabolic dysfunction-associated steatotic liver disease | Hongyan Wu | Not yet recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT05226754 Comparator | Apr 2022 → Jun 2023 | COVID-19 | University of Campinas, Brazil | Unknown | No outcome recorded |
| Phase 2 | NCT02177643 Comparator | Jan 2013 → Aug 2016 | type 2 diabetes mellitus | University of Campinas, Brazil | Unknown | No outcome recorded |
| Phase 2 | NCT03208309 Comparator | Jan 2013 → Aug 2015 | type 2 diabetes mellitus | ANS Pharma | Completed | No outcome recorded |
| Phase 3 | NCT07549386 Comparator | May 2024 → Mar 2025 | osteoarthritis | Laboratorios Liomont | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-08-29 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma Gains Exclusive Rights for Accro's Novel Small-Molecule Drug Candidate AC-201 in Greater China fosunpharma.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 39 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | diacerein | “AC-203 (diacerein 1% ointment) is a topical formulation of diacerein, well-known for its ability to inhibit IL-1β and other proinflammatory cytokines.” NCT06073132 ↗28“Diacerein (Artrodar ®) participants take 1x1 with evening meal for 1 month” NCT04318041 ↗ |
| Known as | AC-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01276106 ↗ |
| Known as | AC-201 CR tablet | “AC-201 CR tablet” NCT02287818 ↗ |
| Known as | AC-203 | “AC-203 (diacerein 1% ointment) is a topical formulation of diacerein, well-known for its ability to inhibit IL-1β and other proinflammatory cytokines.” NCT06073132 ↗ |
| Known as | Artrodar | “Diacerein (Artrodar ®) participants take 1x1 with evening meal for 1 month” NCT04318041 ↗ |
| Known as | DAR | “Diacerein (DAR) is an anthraquinone derivative drug whose active metabolite is rhein.” PMID 32534337 ↗ Jun 2020 |
| Known as | Diacerhein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00440661 ↗ |
| Action | Inhibit | “diacerein, an interleukin-1beta inhibitor” PMID 11710710 ↗ Nov 2001 |
| Modality | Small molecule | “Diacerein, a purified compound with anthraquinonic structure” NCT01120015 ↗ |
| Route | Oral | “oral IL-1beta inhibitor AC-201” NCT01276106 ↗ |
| Target | IL1B | “AC-201 is an IL-1β modulator” NCT01712204 ↗ |